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Analysis of enriched rare variants in 
JPH2-encoded junctophilin-2 among 
Greater Middle eastern individuals 
reveals a novel homozygous variant 
associated with neonatal dilated 
cardiomyopathy
edward G. Jones1, Neda Mazaheri2,3, Reza Maroofian4, Mina Zamani2,3, tahereh Seifi2,3, 
Alireza Sedaghat6, Gholamreza shariati3, Yalda Jamshidi  4, Hugh D. Allen1,5, 
Xander H. t. Wehrens5,7, Hamid Galehdari2 & Andrew p. Landstrom  1,5,8
Junctophilin-2 (JPH2) is a part of the junctional membrane complex that facilitates calcium-handling 
in the cardiomyocyte. Previously, missense variants in JPH2 have been linked to hypertrophic 
cardiomyopathy; however, pathogenic “loss of function” (LOF) variants have not been described. 
Family-based genetic analysis of GME individuals with cardiomyopathic disease identified an Iranian 
patient with dilated cardiomyopathy (DCM) as a carrier of a novel, homozygous single nucleotide 
insertion in JPH2 resulting in a stop codon (JPH2-p.E641*). A second Iranian family with consanguineous 
parents hosting an identical heterozygous variant had 2 children die in childhood from cardiac failure. 
To characterize ethnicity-dependent genetic variability in JPH2 and to identify homozygous JPH2 
variants associated with cardiac disease, we identified variants in JPH2 in a worldwide control cohort 
(gnomAD) and 2 similar cohorts from the Greater Middle East (GME Variome, Iranome). These were 
compared against ethnicity-matched clinical whole exome sequencing (WES) referral tests and a case 
cohort of individuals with hypertrophic cardiomyopathy (HCM) based on comprehensive review of 
the literature. Worldwide, 1.45% of healthy individuals hosted a rare JPH2 variant with a significantly 
higher proportion among GME individuals (4.45%); LOF variants were rare overall (0.04%) yet were most 
prevalent in GME (0.21%). The increased prevalence of LOF variants in GME individuals was corroborated 
among region-specific, clinical WES cohorts. In conclusion, we report ethnic-specific differences in 
JPH2 rare variants, with GME individuals being at higher risk of hosting homozygous LOF variants. This 
conclusion is supported by the identification of a novel JPH2 LOF variant confirmed by segregation 
analysis resulting in autosomal recessive pediatric DCM due to presumptive JPH2 truncation.
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Dilated cardiomyopathy (DCM) is defined as a primary myocardial disorder characterized by ventricular dilation 
and impaired contractility not explained by abnormal loading conditions or ischemic insult1. DCM is attrib-
utable to both genetic and nongenetic causes and is found to be familial in about 25 to 50% of patients2–4. Of 
these familial cases, up to 37% have a clinically relevant genetic variant, leaving the majority of cases genetically 
unexplained5. DCM is a genetically heterogenous disease with disease-associated genes ranging from sarcomeric 
structure to metabolic etiologies to MAPK pathways. One such category includes genes encoding for proteins in 
calcium (Ca2+)-signaling, and -sensitive, pathways, such as JPH2-encoded junctophilin type 2 (JPH2)6.
JPH2 is a striated muscle-specific protein and a critical member of the junctional membrane complex (JMC) 
that regulates myocardial excitation-contraction (E-C) coupling7,8. Cardiac contraction is dependent on effi-
cient E-C coupling which is mediated by Ca2+. Ca2+ influx through voltage-gated L-type calcium channels in 
the t-tubular plasma membrane triggers further Ca2+ release via the ryanodine receptor 2 in the sarcoplasmic 
reticulum9,10. JPH2 anchors the junction between t-tubular sarcolemma and the sarcoplasmic reticulum as well as 
stabilizes the ryanodine receptor 28,11,12. Early studies have suggested a role for JPH2 in the development of DCM, 
with loss of normal JPH2 expression during pathologic remodeling13–16. The importance of JPH2 in the structural 
and functional integrity of the JMC is further reinforced clinically by the observation of disease-associated vari-
ants in JPH2 found in a small number of patients with cardiomyopathy as well as atrial fibrillation11,17–20.
The clinical expansion of broad genetic sequencing, such as whole exome sequencing (WES), has allowed for 
rare causes of cardiomyopathy to be identified and research-based exome sequencing has identified rare variants 
in disease-associated genes. Despite a greater incidence of autosomal recessive disease-causing variants, regions 
such as the Greater Middle East (GME) remain underrepresented and understudied21–23. In this study, we identify 
two Iranian families hosting a novel loss-of-function (LOF) JPH2 variant that, when homozygous, was associated 
with DCM and death in early childhood from cardiac failure. We then systematically examine the background 
frequency of rare variants of JPH2 in regionally diverse populations as well as clinical WES sequencing referrals, 
including those from the GME. We conclude that there are ethnic-specific differences in rare JPH2 variants, with 
GME individuals being at higher risk of hosting homozygous LOF variants.
Methods
study cohorts. This research study was approved by the Baylor College of Medicine and the Ahvaz 
Jundishapur University of Medical Sciences Institutional Review Boards. For genetic studies involving cohorts, 
informed consent was waived. For WES studies, informed consent was obtained. All experiments were performed 
in accordance with relevant guidelines and regulations.
Population-based control cohorts. Worldwide, population-based, control variants were derived from the 
Genome Aggregate Database (gnomAD) made up of 138,632 individuals as well as regionally-specific cohorts24. 
While the gnomAD database is comprised partly of various disease-specific cohorts in addition to population 
genetics studies, it excludes individuals known to have severe pediatric disease as well as severe disease in their 
first-degree relatives; therefore, we utilized these individuals as “control” or “reference” alleles. Furthermore, 
although this database includes many geographically distinct cohorts, the GME is under-represented within gno-
mAD and individuals from this region are not clearly delineated. Thus, variants of ostensibly healthy individuals 
from GME were derived from the GME Variome (N = 1,111)21 and Iranome (N = 800)25, respectively. The GME 
Variome includes individuals from a large collection of Arab and non-Arab Muslim countries (Morocco, Algeria, 
Tunisia, Libya, Egypt, Turkey, Syria, Lebanon, Israel, Saudi Arabia, Iraq, Qatar, Kuwait, Yemen, UAE, Iran, Oman, 
and Pakistan), and excludes individuals with a genetic kinship coefficient suggestive of a high degree of related-
ness. Given overlap in the population of GME Variome and the African/African American population of gno-
mAD, Iranome was included to control for the population solely from Iran. For population frequency calculations 
of “rare variants,” a minor allele frequency (MAF) of <0.01 was utilized. In total, 140,543 individuals across these 
3 cohorts were included as controls.
Baylor and Iranian whole exome sequencing cohorts. Given widespread advancement in clinical WES testing, we 
determined the frequency of JPH2 variants in 2 clinical WES referral cohorts. The Baylor clinical WES cohort has 
been previously described26 and is derived from WES variant data compiled by Baylor Genetics Laboratories27. 
This cohort was comprised of 7,066 probands referred for WES genetic testing to the Baylor Genetics Laboratories 
(Houston, Texas, United States) independent of referral diagnosis or indication for genetic testing. Individuals 
included in this cohort were genetic testing probands. Demographic and clinical referral information was 
abstracted. Genetic information from samples derived for platform validation studies, or from oncological sam-
ples, was excluded. For GME-matched WES referral variants, a cohort of 823 clinical WES referrals from Iran 
were analyzed. Variants included in these WES cohorts were (1) identified in the coding nucleotide sequence or 
predicted splice junction of an HCM-associated gene locus, (2) potential splice donor or splice acceptor-effecting 
variants located within the first four nucleotides near the splice junction, and (3) deemed “pathogenic”, “likely 
pathogenic”, or “variant of uncertain significance” (VUS) at the time of genetic testing according to the American 
College of Medical Genetics (ACMG) criteria/interpretation guidelines28,29, and (4) included on the clinical 
report sent, or made available, to the referring provider. Variants excluded from this study were: (1) interpreted as 
“not pathogenic” at the time of genetic testing, (2) non-splice site intronic variants, (3) 5′or 3′ untranslated region 
variants, or (4) synonymous variants. To account for changes in evidence of pathogenicity since the initial variant 
identification and classification at the time of genetic testing, each variant in the Iranian and Baylor WES cohorts 
was subjected to further verification for pathogenicity via ClinVar aggregate records30. All variants classified as 
“benign” or “likely benign” as of January 23, 2019 were excluded.
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Pathogenic variant cohort. To determine the prevalence of cardiomyopathy-associated JPH2 variants, previ-
ously published studies were utilized11,17,18. A combined prevalence from these cohort-based studies was created. 
Inclusion criteria were (1) associated with a proband/family with a clinical diagnosis of hypertrophic or dilated 
cardiomyopathy, (2) absence of a compound variant deemed to be a likely disease-associated variant, (3) absence 
of the variant in reference/control alleles, and (4) identified in a cohort-based study. Variants obtained from 
non-cohort-based studies that otherwise met inclusion criteria were utilized for non-prevalence analyses.
Whole exome sequencing. Clinical WES testing was conducted as previously described for the Baylor 
WES cohort27. Briefly, extracted DNA was subjected to an in-house exome capture platform (VCRome version 
2.1) and sequenced using either an Illumina Genome Analyzer IIx platform or the Illumina HiSeq 2000 platform. 
Samples were additionally analyzed by an Illumina HumanExome-12 v1 cSNP array for quality-control assess-
ment of exome data, as well as for detecting large copy-number variants and regions of absence of heterozygo-
sity. Iranian clinical WES testing utilized commercial platforms (Beijing Genomic Institute, Shenzhen, China; 
Macrogen, Seoul, South Korea)30. WES performed on DNA from the proband of the first family; the second fam-
ily (Family 2) had WES performed on parents due to unavailability of samples from deceased children. Haplotype 
analysis was performed as previously described31. Presence or absence of putatively pathogenic variants were 
compared against the 1000 Genomes Project32, NHLBI GO Exome Sequencing Project, gnomAD, as well as the 
ethnically-matched GME Variome and Iranome. Confirmation of the WES-identified JPH2-p.E641* variant was 
conducted in the probands of each kindred using direct Sanger sequencing. Further, variant positivity was evalu-
ated in all kindred using Sanger sequencing.
Nomenclature. LOF variants were defined as variants that are predicted to cause a protein loss-of-function 
including nonsense (early termination), insertion/deletion (both in-frame and out-of-frame), and predicted 
canonical splice site variants. Among WES variants, designations of pathogenic, likely pathogenic, or VUS 
were based on the designation at the time of WES testing. Variant annotations were based on established 
nomenclature33.
Sequence homology and domain mapping. JPH2 consensus primary sequence (NM_020433, 
NP_065166) was utilized from the Ensembl browser34. Variants were mapped along the protein topology. Primary 
sequence conservation among 56 independent JPH2 orthologues was compared to determine degree of conserva-
tion across species using the National Center for Biotechnology Information (NCBI).
statistics. Statistical results were expressed as mean with variance expressed as standard deviation or median 
and interquartile range (brackets), as appropriate. Variance of prevalence/proportion was expressed as the exact 
95% confidence interval around proportion when statistical comparisons were made (brackets). Comparisons 
were made by Student’s t-Test, Fisher’s Exact test, Chi-Square with Yates Correction, as appropriate using 
OpenEpi35. Statistical significance threshold was set at P < 0.05.
Results
Identification of a homozygous JPH2-p.E641* variant in an infant with DCM. The proband 
demonstrated severe left ventricular (LV) dilation with rapidly declining systolic function as an infant. He ini-
tially presented at 20 months of age after being hospitalized with fever, tachypnea, and restlessness. Imaging tests, 
including chest radiographs, electrocardiogram, and echocardiography, confirmed the diagnosis of DCM. By 4.5 
years of age, LV systolic function was severely depressed with medically-refractory heart failure (Fig. 1A–C). A 
representative electrocardiogram demonstrating PR-prolongation, conduction delay, and T-wave abnormalities is 
depicted in Fig. 1D. The patient was referred for cardiac transplantation; however, the patient ultimately died at 5 
years of age while awaiting transplant. This child was the offspring of consanguineous parents (first cousins) who 
had 2 affected sons. The pedigree is depicted in Fig. 2A. The mother (III-7) had 4 total pregnancies, with 1 spon-
taneous abortion at 8 weeks (IV-1), and 3 live births. The second affected pregnancy was an infant boy (IV-2) who 
presented with sudden fever, poor feeding, jaundice, and hypotonia as a neonate. He had cardiomegaly, clinical 
features consistent with cardiomyopathy, and died at 37 days of age after a cardiorespiratory arrest. Subsequently, 
the mother gave birth to the proband (IV-3).
Genetic testing for genes canonically associated with DCM were negative for likely pathogenic variants. WES 
was performed and the proband was found to host a homozygous single nucleotide insertion (c.1920dupT) 
resulting in a premature stop codon (JPH2-p.E641*) (Fig. 2B,C; Supp. Fig. 1). The proband hosted no other 
pathogenic variants in currently known monogenic disease-causing genes identified on WES. This JPH2 variant 
is novel and absent in 299,100 reference alleles derived from healthy individuals. JPH2-p.E641* localizes to the 
C-terminal divergent region in an area of low sequence homology and relatively high variation. Segregation anal-
ysis was performed for the variant to determine the mode of inheritance. Although no genetic information was 
available for the family’s first and second children (IV-1, IV-2), both parents and their fourth child (III-6, III-7, 
IV-4) were found to be heterozygous for JPH2-p.E641*. Additionally, this variant was found in the heterozygous 
state in 8 of 32 healthy family members of the proband who were available for genetic screening. These findings 
suggest an autosomal recessive mode of inheritance with functional genetic truncation of JPH2 associated with 
neonatal cardiomyopathy.
JPH2-p.E641* variant possibly associated with rapid ventricular failure in neonatal Ebstein 
anomaly. Supporting the hypothesis that homozygous JPH2-p.E641* is associated with cardiac failure, we 
identified a second consanguineous Iranian family with this variant (Fig. 3). This family was seemingly unrelated 
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Figure 1. (A–C) Transthoracic echocardiography images of the JPH2-p,E641* homozygous variant-positive 
proband demonstrating a severely dilated left ventricle with reduced systolic function and D, 12-lead ECG 
demonstrating bi-atrial dilation, PR-prolongation, interventricular conduction delay, and T wave abnormalities.
Figure 2. (A) Family 1 pedigree of the JPH2-p.E641* homozygous variant-positive proband and extended 
kindred. Arrow denotes proband; gray fill, fetal loss; black fill, dilated cardiomyopathy; diagonal line, deceased. 
(B) Sanger sequence chromatograms depicted wild type JPH2 as well as JPH2-p.E641* heterozygous and 
homozygous sequencing. (C) Linear topology with protein functional domains of JPH2 are depicted with 
location of p.E641* variant (red line) in the divergent region.
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to the previous family although they shared a similar ethnic background (Lor – a group of Iranian people found 
predominantly in southwest Iran). The first child of the mother and father (first cousins once-removed) presented 
at 6 months of age with fever, restlessness, and poor feeding following a sandstorm. His clinical status continued 
to decline after admission, and he eventually died from in-hospital cardiac arrest 3 days later. The second preg-
nancy was prenatally diagnosed with Ebstein anomaly and the child initially did well until 2 years of age when 
he underwent tricuspid valve annuloplasty and atrial septal defect closure. Post-operatively, he had episodes of 
respiratory distress and gradually developed fluid-filled blisters on his skin and had generalized edema involving 
hands, feet, face and abdomen. He developed progressive ventricular failure and died at 2.5 years of age due to 
a cardiac arrest. DNA was not obtained on either child; however, both parents were found to be heterozygous 
for JPH2-p.E641*. Extended segregation analysis identified 2 heterozygous carriers out of 9 additional healthy 
family members of the proband who did not have cardiomyopathy or history of cardiac disease and were able to 
undergo genetic testing. Haplotype analysis using rare variants identified in the WES data from the proband of 
Family 1, and the parents of Family 2 showed an identical haplotype containing the JPH2 variant, indicative of a 
founder effect.
JPH2 demonstrates ethnic-specific variability in genetic sequence. Given our findings of a trun-
cating LOF JPH2 variant associated with cardiac death early in childhood in two GME families, we next sought to 
characterize the differences in genetic variation of JPH2 amongst ethnically distinct populations. We first exam-
ined the frequency of rare JPH2 variants in several population-based genomic studies of control individuals. 
Among 138,632 individuals genotyped in the gnomAD cohort, there were 2,015 variants with a MAF < 0.01 
that contributed to a total rare variant frequency of 1.45% [1.39–1.52]. When divided by regional subtypes, the 
highest prevalence of rare JPH2 variants was found in African American/African individuals (5.03% [4.65–5.43]) 
followed by European (Finnish) (1.74% [1.51–1.96]). Given the underrepresentation of GME individuals within 
gnomAD, and recent evidence of high genetic variation and autosomal recessive variants21, we next evaluated 2 
additional GME-specific databases. Of the 1,111 individuals in the GME Variome cohort, there were 50 variants 
with a MAF < 0.01 leading to a total variant frequency of 4.50% [3.28–5.72]. Due to potential overlap between the 
GME Variome population and African/African American subgroup of gnomAD, the Iranome cohort was also 
included. The Iranome cohort demonstrated 35 variants found within 800 individuals providing a prevalence 
of 4.38% [2.96–5.79]. The GME Variome and Iranome cohorts each demonstrated a higher overall prevalence 
of JPH2 variants than any gnomAD subgroup other than African American/African (P < 0.001). There was no 
difference between GME Variome and Iranome JPH2 variant frequency.
Given the high prevalence of rare variants within control individuals, we next evaluated these cohorts for rare 
LOF variants. The incidence of LOF variants was rare within the gnomAD cohort with a prevalence of 0.04% 
[0.03–0.05]. In comparison, the Iranome cohort contained 3 identified LOF variants for an overall prevalence of 
0.375% [0.00–0.80], nearly 10-fold the prevalence seen in gnomAD cohort. This was significantly higher than all 
regional groups except European (Finnish) (0.16%, [0.09–0.22]) (P < 0.001). The GME Variome hosted 1 LOF 
variant (0.09% [0.00–0.27]). For the purposes of comparison, both the GME Variome and Iranome were com-
bined into a “GME Healthy Cohort” that had an overall JPH2 variant prevalence of 4.45% [3.52–5.37], with a 
LOF variant prevalence of 0.21% [0.01–0.41]. All LOF variants in control cohorts were heterozygous. There was 
a single truncating LOF variant noted in the GME Healthy Cohort. However, there were 25 total individuals in 
the gnomAD cohort (0.02% [0.01–0.03]) hosting heterozygous truncating variants, 18 of which were Finnish. 
There were no homozygous truncating variants noted in any control cohort. These results are summarized in 
Fig. 4A. Taken together, these results indicate a greater burden of JPH2 variation in healthy individuals from GME 
regions, particularly in LOF variants.
Figure 3. Family 2 pedigree of the GME family with both consanguineous parents hosting heterozygous 
JPH2-p.E641* variants. Arrow denotes proband; gray fill, cardiac arrest; black fill, Ebstein anomaly with rapidly 
progressive dilated cardiomyopathy; diagonal line, deceased.
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Variants in JPH2 demonstrate ethnic-specific variability among clinical WES referrals. Due to 
widespread advancement in clinical WES testing, we next compared these findings to the frequency of identified 
variants within regionally-matched cohorts of clinical WES referrals. Among 7,066 unrelated probands undergo-
ing clinical WES testing at Baylor College of Medicine, 167 probands hosted a JPH2 variant (2.36% [2.01–2.72]), 
including 10 probands with LOF variants (0.14% [0.05–0.23]). These were both modestly higher than the total 
variant prevalence and LOF variant prevalence observed in the gnomAD cohort (P < 0.001). Similarly, among 
823 Iranian clinical WES referrals, 24 probands hosted a rare variant of JPH2 (2.92% [1.77–4.07]), 6 of which were 
LOF (0.73% [0.15–1.31]). Among the 6 LOF variants identified within the Iranian WES cohort, two were JPH2-p.
E641* variants – one from each of the two families described above. One JPH2-p.E641* variant represents the 
homozygous affected proband from Family 1, whereas the second variant represents a heterozygous unaffected 
parent from Family 2 with evidence of two infant deaths related to cardiac failure. All LOF variants identified 
in clinical WES cohorts are detailed in Table 1. Between these 2 clinical WES cohorts, there was no significant 
difference in prevalence of total variants; however, the Iranian WES cohort demonstrated a significantly higher 
prevalence of LOF variants (P < 0.001). Overall, this indicates a higher incidence of JPH2 LOF variants in GME 
individuals referred for clinical genetic testing in independent region-specific cohorts, corroborating a similar 
finding in population-based, ostensibly healthy individuals. These results are summarized in Fig. 4B.
Frequency of JPH2 variants among cases of cardiomyopathy. Due to the high background rate of 
rare variants in JPH2, we explored the rate of pathogenic JPH2 variants found in patients clinically diagnosed with 
cardiomyopathy. Of the 981 individuals with cardiomyopathy in the HCM cohort, only 6 (0.61% [0.12–1.10]) 
hosted a JPH2 variant, all of which were heterozygous missense variants. This was significantly lower than the 
prevalence demonstrated in gnomAD (1.45%, P < 0.05), the GME Healthy cohort (4.45%, P < 0.001), and both 
of the clinical WES cohorts (WES-Iran 2.92%, WES-Baylor 2.36%, P < 0.001). No LOF variants were described. 
These results are summarized in Fig. 4B. Importantly, of the 6 cardiomyopathy-associated variants identified, 
only 1 was also found to be present in control cohorts (JPH2-A405S, gnomAD MAF = 9.69E-05). None of the 7 
cardiomyopathy-associated variants were found in the GME Variome or Iranome cohorts. Taken together, these 
results suggest that pathogenic JPH2 variants are rare among patients with cardiomyopathy and are largely absent 
in population and clinical WES-based cohorts.
Comparison of genetic variability, orthologue identity, and variant topology. To characterize 
the genetic variation found in JPH2, amino-acid level sequence homology analysis was performed to correlate 
with genetic variation. The structure of JPH2 is comprised of 8 membrane occupation and recognition nexus 
(MORN) domains that associate with the t-tubule at the N-terminus, a C-terminal transmembrane domain 
that anchors into the sarcoplasmic reticulum, and an alpha-helical domain that spans the junctional space in 
between8. We observed the highest degree of sequence homology in the MORN domains, followed by the trans-
membrane and alpha-helix domains. There was markedly less sequence homology demonstrated in the linker 
Figure 4. (A) Bar graph comparing the frequencies of rare JPH2 variants in ostensibly healthy individuals. 
The gnomAD cohort is broken down into 8 ethnic subgroups. GME Variome and Iranome represent 2 
independent Middle Eastern cohorts. No fill, total frequency; tan, missense variant frequency; red, LOF variant 
frequency. Error bars denote 95% CI; *P < 0.05, **P < 0.001 compared to European (Non-Finnish). (B) Bar 
graph comparing the frequencies of JPH2 variants in a GME Healthy Cohort (GME Variome + Iranome), an 
ostensibly healthy population (gnomAD), a cohort of clinical WES referrals at Baylor College of Medicine 
(WES), a cohort of clinical WES referrals from Iran (WES-Iran), and a population of those diagnosed with 
HCM. Error bars denote 95% CI; *P < 0.05, **P < 0.001 compared to gnomAD.
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and divergent domains. We next overlaid the prevalence of all variants in individuals from the gnomAD cohort 
by amino acid, including those above the MAF threshold, which revealed generally higher levels of genetic 
variability in regions with less sequence homology, such as the linker region. There were 2 common variants 
within the gnomAD cohort with MAF > 0.01 included in this analysis, JPH2-A396T (MAF = 0.179) and G505S 
(MAF = 0.011). Amino acid positions containing LOF variants found in ostensibly healthy individuals as well as 
disease-associated variants were also mapped. Both the LOF and the disease-associated variants did not appear 
to localize to areas of high homology nor to areas of high genetic variability. These results are summarized in 
Fig. 5. Overall, these findings suggest that areas of high sequence variation correspond to areas less conserved 
across species. However, both cardiomyopathy-associated variants and LOF variants found in ostensibly healthy 
individuals do not seem to localize to specific “hot spots” on the protein.
Nucleotide Amino Acid Zygosity
Baylor WES Cohort
c.1778_1779insGGTCCG p.E593delinsGSE Het
c.1819_1820insACCGCCCCGCT p.P607delinsTAPLQAP Het
c.349_351del p.117del Het
c.349_351del p.117del Het
c.516_517insAGCAAC p.G173delinsSNG Het
c.516_517insAGCAAC p.G173delinsSNG Het
c.517_518insAGCAAC p.G173delinsSNG Het
c.517_518insAGCAAC p.G173delinsSNG Het
c.517_518insAGCAAC p.G173delinsSNG Het
c.55del p.E19fs Het
Iranian WES Cohort
c.1878_1879insC p.I627fs Het
c.1920dupT p.E641* Hom#
c.1920dupT p.E641* Het##
c.511_516dupAGCAAC p.S171_N172dup Het
c.511_516dupAGCAAC p.S171_N172dup Het
c.864_865insACCACC p.T288_E289insTTT Het
Table 1. Loss of Function Variants Identified in WES Cohorts. WES, whole exome sequencing; Het, 
heterozygous; Hom, homozygous; #proband from Family 1; ##parent from Family 2.
Figure 5. Amino-acid level genetic variability analysis of JPH2. Functional domains of JPH2 are depicted. 
Ortholog identity map and prevalence of variants in healthy individuals (gnomAD) by amino acid are depicted 
with orange lines representing rolling averages. Amino acid positions containing radical variants found in 
ostensibly healthy individuals and disease-causing variants found in those with cardiomyopathies are depicted, 
with those in red representing variants identified in individuals from the Middle East. MORN, membrane 
occupation and recognition nexus domain; TM, Transmembrane domain. *MAF exceeding Y-axis.
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Discussion
In this study, for the first time to our knowledge, we present a novel homozygous LOF JPH2 variant, JPH2-p.E641*, 
associated with autosomal recessive DCM in an Iranian family, confirmed by segregation analysis. This finding was 
further supported by a second Iranian family where both healthy parents carry the same LOF JPH2 variant and 
who had 2 children who died in early childhood from cardiac failure, 1 in the context of structural heart disease. In 
the case of this novel truncating nonsense variant, it is possible that the homozygous loss of the C-terminal trans-
membrane domain in individuals hosting JPH2-p.E641* causes loss of anchoring to the sarcoplasmic reticulum, 
resulting in impaired Ca2+ handling and increased risk of heart failure early in life. Prior to these observations, only 
heterozygous missense JPH2 variants have been linked to a cardiomyopathy phenotype11,17–19.
In the setting of these findings, a growing body of evidence has demonstrated that alterations in JPH2 expres-
sion and function can perturb intracellular Ca2+ signaling and result in myopathic disease, including HCM and 
DCM12,36. JPH2-null mice demonstrate embryonic lethality due to molecular failure of the JMC and ineffec-
tive Ca2+-signaling needed to sustain EC coupling and cardiac contractility7,15. Furthermore, induction of JPH2 
expression silencing in adult mice is associated with rapid deterioration into heart failure with a dilated left ven-
tricle and loss of systolic function16,37. When combined with the striking phenotype observed in the 2 families 
presented here, which mimic these rodent models, our findings support the concept that loss of JPH2 expression 
can result in rapid progression of cardiomyopathy and heart failure. Additional studies utilizing in vitro and in 
vivo models are needed to fully explore this possible mechanism disease.
The investigation of pathogenic JPH2 variants in individuals with cardiomyopathies has temporally coin-
cided with a recent increase in clinical utilization of next-generation sequencing modalities. Tools like WES 
not only increase the sensitivity for detecting genetic variants in atypical clinical presentations, but also have 
given us a window into the natural variability of human genome and how it varies by geographic and ethnic 
backgrounds24,38. Based on the underrepresentation of GME populations in current large-scale public genome 
databases, and the relatively high density of genetic disease within the GME population, we sought to examine 
whether significant genetic variability in JPH2 existed between GME and other ethnic populations. Remarkably, 
we found a high burden of genetic variation, including LOF variants, within cohorts representing the GME. 
The higher prevalence of LOF variants was replicated in clinical genetic testing referrals and may contribute to 
an overall increased risk of development of JPH2-related AR cardiomyopathy in those with GME/Iranian eth-
nic backgrounds. These observations highlight the critical nature of comparing disease-associated variants with 
ethnically-matched control alleles. This is reflected in the American College of Genetics and Genomics recom-
mendations to include race-matched control data when interpreting sequence variants39.
The variants from WES cohorts in JPH2 are difficult to interpret, particularly in individuals with a low pre-test 
probability of disease. Previously there has been evidence to suggest that incidentally identified variants in chan-
nelopathies likely represent background genetic variation26,40 Both clinical WES cohorts hosted variants at a 
markedly higher rate than cardiomyopathy cases, which supports the hypothesis that the majority of these JPH2 
variants also represent background noise. The requirement of the truncating variant JPH2-p.E641* to be homozy-
gous in order to produce clinical disease also suggests that previously described heterozygous missense variants 
may result in disease through a dominant-negative effect41. However, the challenge in clinical evaluation of chil-
dren who may develop a cardiomyopathy phenotype later in life must be recognized. Furthermore, the presence 
of variants in phenotype-negative individuals does not necessarily exclude variant pathogenicity, as is seen in 
TTN truncating variants that have been shown to cause DCM despite their presence in up to 1% of the general 
population42. This highlights the need for more research to improve identification of susceptibility alleles and the 
role that missense JPH2 variants play in contributing to cardiomyopathies.
Previous studies in arrhythmogenic disorders have demonstrated the value of mapping variant locations 
in assessing for risk of pathogenicity, suggesting that some regions of disease-causing genes may have elevated 
signal-to-noise ratios26,43. In an effort to characterize the genotype-phenotype mechanism of this study’s novel LOF 
variant, we stratified JPH2 variant analysis at the amino acid level and compared it to other previously identified var-
iants. We found that both LOF and disease-causing variants did not cluster in areas of either increased homology or 
increased variance, nor did they localize to a specific protein motif. Combined with the many healthy Iranian family 
members that hosted a single copy of JPH2-p.E641*, this reinforces the likelihood that a heterozygous LOF variant 
would be insufficient to cause disease. Additionally, while the number of pathogenic and LOF variants are relatively 
small, these results suggest that there are no specific disease-associated “hotspot” domains in JPH2.
This study has several limitations. First, the supporting evidence that the second Iranian family provides in 
the potential pathogenicity of JPH2-p.E641* is limited by the lack of genotype on any of the diseased offspring 
noted. However, the presence of additional healthy heterozygous individuals, when combined with the inci-
dence of multiple presumed cardiac deaths in childhood in the offspring of two heterozygous parents, warranted 
inclusion of the family in the study. Second, this study uses a MAF of <0.01 as an upper threshold for inclu-
sion of rare variants in control cohorts. Though a MAF threshold of <0.0001 has previously been validated for 
rare cardiomyopathy-associated variants44, this upper bound was not feasible given the smaller size of the GME 
Variome and Iranome cohorts. The large difference in the size of these cohorts makes comparison challenging and 
is a result of the underrepresentation of GME individuals in larger genomic databases. This emphasizes the need 
for further large-scale investigation into this population.
Conclusions
Our findings add to the growing evidence that variants in JPH2 play a role in cardiomyopathy; and suggest that 
this novel biallelic truncating variant can give rise to severe, early-onset cardiomyopathy. Given the higher prev-
alence of LOF variants identified in ethnically-matched controls, as well as evidence to suggest that heterozygous 
LOF variants are insufficient to cause disease, it is likely that this proband’s risk of disease was exacerbated by their 
ethnic background.
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Data Availability
JPH2-p.E641* proband information has been uploaded to PhenomeCentral45 (https://www.phenomecentral.org) 
under ID number P0008365.
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